Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTSWPH8)

DTT Name	Growth/differentiation factor 8 (GDF-8) DTT Info
Gene Name	MSTN

Molecule-Related Drug & Molecule List

Molecule-Related Drug List

Molecule Type:

DTT

DTP

DME

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

7 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ACE-031	DMZ8PY0	Duchenne dystrophy	8C70	Phase 2	[1]
AMG 745	DMFXN2T	Muscle atrophy	FB32.Y	Phase 2	[2]
Domagrozumab	DMCT08V	Duchenne dystrophy	8C70	Phase 2	[3]
LY2495655	DMM5JAN	Disuse muscle atrophy	8B61	Phase 2	[4]
PF-06252616	DMQLZOF	Duchenne dystrophy	8C70	Phase 2	[4]
SAR391786	DMS1YPZ	Muscle atrophy	FB32.Y	Phase 2	[5]
Stamulumab	DMBCIXL	Duchenne dystrophy	8C70	Phase 1/2	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Clinical Trial Drug(s)

Molecule Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

References

1	A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013 Mar;47(3):416-23.
2	The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011 September; 2(3): 143-151.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360.
5	Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010 Mar;10(1):56-63.